Back

Astrocyte and neurogenic mechanisms of protective gene therapy prevent brain disease and death due to non-ketotic hyperglycinemia

Lopez-Ramirez, A.; Bali, A.; Alam, M. S.; Padmanabhan, P.; Calhoun, S.; Bickerton, C.; Flores-Mireles, A. L.; Haldar, K.

2025-03-31 neuroscience
10.1101/2025.03.26.645560 bioRxiv
Show abstract

Genetic defects in glycine decarboxylase (GLDC) cause non-ketotic hyperglycinemia (NKH), a rare and frequently fatal neurometabolic disease, which lacks FDA-approved therapies. We characterized CRISPR Cas9-edited humanized mice expressing a prevalent clinical mutation after administration with a single intraperitoneal dose of a novel recombinant of adeno-associated viral vector 9 expressing GLDC (rAAV9-GLDC). Long term biological activity of rAAV9-GLDC was first validated by assessment of its systemic efficacy over five and ten months in mice. Access of rAAV9 to the brain was confirmed by tracking green fluorescent protein (GFP) after a single intraperitoneal dose of rAAV9-GFP. Over five months, control mock treated GFP-mice showed reduction in astrocytes but not microglia, oligodendrocytes or neurons in the brain. 37% of these animals suffered long term neurological disease and/or death. rAAV9-GLDC boosts astrogenesis without triggering an inflammatory response and confers 100% protection against disease progression and fatality due to NKH.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
JCI Insight
● 277 papers in training set
Top 0.5%
7.9%
Similar papers in this journal
2
Nature Communications
○ 5641 papers in training set
Top 23%
6.8%
Similar papers in this journal
3
Molecular Therapy
○ 81 papers in training set
Top 0.2%
6.8%
Similar papers in this journal
4
Scientific Reports
○ 3612 papers in training set
Top 12%
6.3%
Similar papers in this journal
5
Neurobiology of Disease
○ 148 papers in training set
Top 0.6%
5.5%
Similar papers in this journal
6
Molecular Therapy - Methods & Clinical Development
○ 38 papers in training set
Top 0.1%
4.9%
7
Human Molecular Genetics
◐ 141 papers in training set
Top 0.6%
3.5%
8
eLife
● 5828 papers in training set
Top 35%
3.2%
9
Journal of Neuroinflammation
○ 61 papers in training set
Top 0.4%
2.8%
10
iScience
○ 1154 papers in training set
Top 11%
2.4%
50% of probability mass above
11
Disease Models & Mechanisms
139 papers in training set
Top 0.9%
2.2%
12
Neurotherapeutics
○ 14 papers in training set
Top 0.1%
2.1%
13
Brain
◐ 168 papers in training set
Top 2%
2.1%
14
Science Advances
● 1243 papers in training set
Top 16%
2.1%
15
Annals of Neurology
○ 64 papers in training set
Top 0.8%
2.1%
16
Cell Reports
○ 1498 papers in training set
Top 18%
1.7%
17
Neuro-Oncology
◐ 36 papers in training set
Top 0.4%
1.7%
18
Molecular Therapy Nucleic Acids
○ 39 papers in training set
Top 0.5%
1.7%
19
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 28%
1.7%
20
Journal of Clinical Investigation
● 179 papers in training set
Top 4%
1.4%
21
Brain Communications
◐ 166 papers in training set
Top 2%
1.3%
22
Molecular Psychiatry
○ 282 papers in training set
Top 4%
1.3%
23
PLOS ONE
● 5266 papers in training set
Top 50%
1.3%
24
The Journal of Neuroscience
● 1025 papers in training set
Top 8%
1.1%
25
Cell Reports Medicine
○ 153 papers in training set
Top 3%
1.1%
26
Experimental Neurology
○ 61 papers in training set
Top 0.9%
1.1%
27
EMBO Molecular Medicine
○ 95 papers in training set
Top 2%
1.0%
28
Fluids and Barriers of the CNS
○ 28 papers in training set
Top 0.4%
0.9%
29
Molecular Therapy Methods & Clinical Development
○ 13 papers in training set
Top 0.2%
0.8%
30
Molecular Neurodegeneration
○ 55 papers in training set
Top 2%
0.8%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.